For [177Lu]Lu-PSMA-617 and [177Lu]Lu-DOTA-TATE, approximately half of patients are estimated to be either under or overtreated with the standard protocols (intravenous administration of 7.4 GBq every six weeks for [177Lu]Lu-PSMA-617, or every eight weeks for [177Lu]Lu-DOTA-TATE) [72], and about two-thirds of the cumulative tumour absorbed dose is delivered within the first two cycles [73]. This evidence concerns the gene FOLH1 and neoplasm.